Glax­o­SmithK­line joins So­sei's who's-who list of clients with glob­al li­cens­ing pact for IBD small mol­e­cules

Big drug­mak­ers are on the hunt for nov­el ther­a­peu­tics in a range of ul­tra-com­pet­i­tive ther­a­peu­tic ar­eas. Japan’s So­sei Hep­tares has emerged in re­cent years as a sought-af­ter part­ner for Big Phar­mas seek­ing nov­el neu­ro can­di­dates — but now Glax­o­SmithK­line wants to try the pre­clin­i­cal R&D ex­pert’s work in in­flam­ma­to­ry bow­el dis­ease.

GSK has tapped So­sei Hep­tares for dis­cov­ery work tar­get­ing IBD and oth­er gas­troin­testi­nal im­mune dis­or­ders with small-mol­e­cule ag­o­nists for GPR35, an or­phan G pro­tein-cou­pled re­cep­tor (GPCR) with a ge­net­ic link to those con­di­tions, the com­pa­nies said Sun­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER